Study on Gene Evolution in Glioma Under Stress Therapy

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 17, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Genetic Change
Interventions
DRUG

Gene evolution and molecular response under Bevacizumab treatment

Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \* 150mg/m2/day BSA(Body Surface Area)=\[weight (kg)\* height (cm)/3600\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes

Trial Locations (1)

450003

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER

NCT05512325 - Study on Gene Evolution in Glioma Under Stress Therapy | Biotech Hunter | Biotech Hunter